http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Pfizer (PFE) to Acquire Privately-Held Amplyx Pharmaceuticals
-
Pfizer Acquires Amplyx Pharmaceuticals
-
Pfizer Declares Second-Quarter 2021 Dividend
-
Pfizer (PFE) and BioNTech (BNTX) to Supply EU with 100 Million Additional Doses of COVID-19 Vaccine
-
Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®
-
Pfizer Invites Shareholders to Attend Virtual-Only 2021 Annual Meeting of Shareholders on April 22
-
Myovant Sciences (MYOV), Pfizer (PFE) Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
-
Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
-
Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
-
Pfizer (PFE) Announces Extension of Review of NDA of Abrocitinib for Treatment of Moderate to Severe Atopic Dermatitis
-
Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for the Treatment of Moderate to Severe Atopic Dermatitis
-
Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Review Oncology Business on April 9, 2021
-
Pfizer (PFE) and BioNTech (BNTX) Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study
-
Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study
-
Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study
-
Pfizer (PFE), BioNTech (BNTX) COVID-19 Vaccine 100% Effective in Adolescents 12 to 15 Years of Age, Trial Shows
-
Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents
-
Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents
-
EMA Approves New Storage Option for Pfizer-BioNTech Vaccine, Easing Distribution and Storage of Doses Across European Union
-
Pfizer (PFE), Lilly (LLY) Announce Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain
-
Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain
-
Pfizer (PFE) Announces Real-World Evidence Supports Effectiveness of First-line IBRANCE Combination Therapy in HR+, HER2- Metastatic Breast Cancer
-
Real-World Evidence Supports Effectiveness of First-line IBRANCE® (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer
-
Myovant Sciences (MYOV), Pfizer (PFE) Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
-
Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
-
Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
-
Pfizer (PFE) Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2
-
Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2
-
Pfizer Invites Public to View and Listen to Webcast of Pfizer May 4 Conference Call with Analysts
-
Exelixis (EXEL) Announces Pact with Merck KGaA and Pfizer (PFE) to Evaluate XL092 and Avelumab in Various Forms of Locally Advanced or Metastatic Urothelial Carcinoma
-
Real-World Evidence Confirms High Effectiveness of Pfizer (PFE) -BioNTech (BNTX) COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared
-
Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared
-
Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared
-
Transgene Expands Phase II Clinical Trial of Therapeutic Vaccine TG4001 in Combination With Avelumab Versus Avelumab Monotherapy in Patients With HPV16-positive Anogenital Cancers
-
Pfizer (PFE) and Valena Begin Phase 2 Study for Lyme Disease Vaccine Candidate
-
Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate
-
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
U.S. FDA Expands Approval of Pfizer’s LORBRENA® as First-Line Treatment for ALK-Positive Metastatic Lung Cancer
-
European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older
-
Pfizer (PFE) and OPKO (OPK) Announce EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
-
EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
-
Pfizer (PFE), BioNTech (BNTX) Initiate Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants
-
Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants
-
Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants
-
Seven Bridges Selected by Pfizer to Support Data Management Solution for Single-Cell RNA Sequencing Data
-
Pfizer (PFE) Announces U.S. FDA Accepts for Priority Review of Application for TicoVac
-
U.S. FDA Accepts for Priority Review Pfizer’s Application for TicoVac™ (Tick-borne Encephalitis Vaccine)
-
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
Pfizer (PFE) and BioNTech (BNTX) Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA
-
Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA

